Amgen "market perform"

31.12.07 - Rodman & Renshaw

NEW YORK, December 31 (newratings.com) - Analysts at Rodman & Renshaw maintain their "market perform" rating on Amgen Inc (AMGN).

In a research note dated December 30 and published this morning, the analysts mention that Aranesp?s November sales declined by 2.8% m/m in November and are tracking below the 4Q07 estimate of $465 million. The monthly sales of Amgen?s Epogen and Neulasta grew on an m/m basis, while sales of Enbrel, Vectibex and Neupogen declined, the analysts add.